Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane®
(nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and
tolerability. When combined with a taxane, platinum agents improve response in metastatic
breast cancer, with carboplatin conferring less toxicity than cisplatin. The investigators
hypothesize that the combination of weekly Abraxane® and carboplatin will lengthen time to
progression without producing intolerable toxicity.